B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma
Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-year survival rate less than 10% because of lacking effective treatment. Here, we aimed to explore whether B7-H3 could serve as a novel therapeutic target for GBM in chimeric antigen receptor (CAR) T cell therapy...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | Molecular Therapy: Oncolytics |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770519300683 |